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THE PREVALENCE OF METABOLIC SYNDROME IN YOUNG ACUTE                
CORONARY SYNDROME PATIENTS 
INTRODUCTION: The metabolic syndrome (syndrome X, insulin resistance 
syndrome) consists of a constellation of metabolic abnormalities that confer 
increased risk of cardiovascular disease (CVD) and diabetes mellitus. The prevalence 
of the metabolic syndrome varies around the world, depending on the age and 
ethnicity of the populations studied and the diagnostic criteria applied 
AIM: To ascertain the prevalence of metabolic syndrome  in young acute coronary 
syndrome (ACS) patients. 
MATERIALS AND METHODS: Patients aged < 45 years hospitalized with the 
first episode of ACS were categorized based on  the NCEP-ATP III CRITERIA for 
metabolic syndrome. Laboratory assessments included obtaining venous blood 
samples in a fasted state for the determination of lipid components (total cholesterol 
(TC), HDL-C, LDL-C and TG, and total lipid) and blood glucose. Serum glucose and 
lipids were measured by International Federation of Clinical Chemistry approved 
enzymatic methods using commercially available kits. Blood pressure was measured 
using a sphygmomanometer and elevated blood pressure according to NCEP:ATPIII 
was diagnosed if the systolic blood pressure  was higher than 130mmHg or the 
diastolic blood pressure  was above 85 mmHg. Waist circumference  was evaluated 
at midway between the iliac crest and the last rib. 
RESULTS: In our study, the metabolic syndrome, as defined by the NCEP ATP III 
criteria, was found in 23 patients (46%) of the study population. The fasting blood 
glucose was the most common NCEP ATP III determinant elevated in patients with 
or without the metabolic syndrome, about 72%. The prevalence of other components 
were raised triglyceride levels (50%), low HDL cholesterol levels (40%), increased 
waist hip ratio (16%) and elevated systolic blood pressure (48%). The mean age of 
the sample population was 38.48. The mean fasting blood sugar level was found to be 
147.87mg/dl in patients with metabolic syndrome and 116.44 mg/dl in patients 
without metabolic syndrome. 
CONCLUSION: The prevalence of metabolic syndrome in young patients presented 
with acute coronary syndrome was found to be around 46%. The fasting blood 
glucose was the most common NCEP ATP III determinant elevated in patients with 
or without the metabolic syndrome, about 72%. This high prevalence of metabolic 
syndrome in young population reinforces the need for a comprehensive non 
communicable disease prevention and control program. Increasing awareness and 
early identification of the clusters of risk factors should be emphasized in designing 
population wide prevention strategies. When the full spectrum of various aetiological 
factors and risk markers of CVD risk in metabolic syndrome is uncovered, we can 
more effectively implement concrete preventive strategies in the community on a 
wide scale.  
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